Lead fully integrated best-in-class US Market Access group that includes both strategic and operational responsibilities. Provide leadership and strategic direction in developing and executing all US Market Access efforts for new product launches and lifecycle management of marketed products for large Rare Disease portfolio ensuring business objectives and product availability to patients.
Archives: Team
Allison Fuller
Allison leads VPMR in providing top-tier global market research to healthcare, pharmaceutical, biotech, and medical device organizations. With expertise in both quantitative and qualitative methodologies, she oversees company sales, client management, and delivers key insights that support strategic decisions across the life sciences industry. Before founding VPMR, Allison was Group Director at Verispan, leading market research initiatives and developing extensive knowledge in healthcare analytics.
Allison holds a BA from Lehigh University.
Tom McDonnell
Tom is an accomplished life sciences executive whose career in commercial leadership spans more than 20 years. He has held key roles at Shire, where he was the Vice President and General Manager of Vyvanse and Intuniv, and most recently served as Chief Commercial Officer at Neos Therapeutics. Tom possesses deep commercial experience in product launch, sales, marketing, and market access. Over the past 6 years, Tom has led the strategic growth and expansion of Benchworks, including the integration of multiple business units under the agency.
Tom holds a BA from Muhlenberg College
Alexandra Daley
Alexandra is an experienced partner to biotech and pharma, with a focus on driving commercialization and brand success. She is a trusted advisor and strategic marketer with over 25 years of delivering insight-driven solutions. Her leadership has shaped impactful strategies that enable sustainable brand differentiation, activate customers, and drive engagement across the entire product lifecycle. A proven life sciences partner, she specializes in rare disease commercialization—partnering with clients to launch, scale, and lead.
AD is known for her deep commitment to collaboration, and thrives on building strong, trust-based partnerships to bring bold ideas to life.
Alexandra holds a BA from Fairfield University.
Select Achievements
- Led successful commercialization of 6+ rare disease therapies, including first-in-class gene therapies
- Developed breakthrough brand strategies for over 15 clients, resulting in increase in brand preference and accelerated market penetration.
- Developed and managed cross-functional internal teams, creating trust-based leadership approach that delivered exceptional client outcomes and 65% growth in new accounts.
Jess Podgajny
Jess is a seasoned leader passionate about partnering with established and emerging pharma and biotech organizations to catalyze growth and maximize product launch potential.
In her 20+ years as a management consultant partnering with pharmaceutical companies, Jess has led transformational initiatives for global teams in Sales, Marketing, Operations, Strategy, C-Suite, Supply Chain, and HR.
Jess holds a BA from Penn State University.
Greg Lief
Greg founded Asymmetry Group in early 2017 with the mission to provide a differentiated consulting experience to innovative healthcare companies. Greg has devoted 25+ years to growing healthcare companies through industry and management consulting experience, with a particular focus on helping companies launch new therapeutics. Prior to founding Asymmetry, Greg ran Global Commercial Operations at Biogen, and also held leadership positions in Corporate Strategy at Life Technologies and Supply Chain Strategy at Wyeth Biopharma. Greg also spent a decade in strategic management consulting at Monitor Group (now Deloitte Consulting), serving biopharmaceutical, medical device, diagnostic and life science clients. Greg holds an M.B.A. from the Kellogg School of Management at Northwestern University, and a B.A. in Biology and Environmental Studies from Dartmouth College. When he’s not serving clients, you can usually find Greg with his wife and two daughters skiing, climbing and biking in the White Mountains.
Yakir Siegal
Yakir joined Asymmetry Group after serving at Deloitte Consulting as a Managing Director in the Monitor Deloitte Strategy practice. He has worked in a variety of industries since originally joining Monitor Group in 1994, working on corporate and business unit strategy, commercial capability building, marketing and organic growth strategy, stakeholder management, new business development, leadership development, and organizational design. Yakir’s 20+ years of experience in life sciences spans a broad range of therapeutic areas and covers the full spectrum of the product lifecycle, from early commercial input through brand revitalization and lifecycle management. Yakir is a co-author of several articles on topics, including drug pricing and market access, a return on capital view of the US healthcare industry, and the role of business model innovation in MedTech. Yakir received an A.B., A.M., and Ph.D. in Physics from Harvard University, where his research focused on ultrafast laser spectroscopy, semiconductor physics, and nonlinear optics. Yakir and his wife live in Brookline and enjoy traveling around New England and visiting or being visited by their two daughters.
David Pitts
In 2007, Mr. Pitts and Andrea Rabney established Argot Partners as a life scienced-focused strategic communications consultancy to provide clients with a full suite of communications services to help communicate their narratives to key audiences at every stage of the biopharmaceutical lifecycle.
Mr. Pitts co-founded Argot Partners with Ms. Rabney after their close collaboration at ImClone Systems (acquired by Eli Lilly and Company), where they navigated communications for the regulatory failure and ultimate approval of the cancer treatment ERBITUX®, various government investigations, an exploration of strategic alternatives and a consent solicitation by investor Carl Icahn. Mr. Pitts worked for ImClone as a special situations advisor, and subsequently joined the company in 2004.
Mr. Pitts began his career in corporate communications at boutique special situations firm, Sard Verbinnen & Company, and later joined the Abernathy MacGregor Group, ultimately serving as a Senior Vice President. In these roles, he counseled multi-national clients through such matters as mergers and acquisitions, corporate crises, restructurings, proxy contests, initial public offerings, exchange listings and litigation. Mr. Pitts earned his Bachelor of Arts degree in Asian Studies from Trinity College in Connecticut where he graduated with honors and thesis distinctions. He is fluent in French and proficient in Mandarin and Spanish.
Select Achievements
- Advised on numerous transformative communications scenarios in the life sciences, including initial public offerings, key data readouts, regulatory reviews and approval, advisory committees, product launches and M&A
Andrea Rabney
Andrea co-founded Argot Partners in 2007 as a life sciences-focused strategic communications consultancy to help companies of all sizes and stages articulate their science and its value to key stakeholders. She leverages her 30+ years of experience as well as her relationships within the financial industry to counsel clients on matters such as corporate positioning, mergers and acquisitions, financings and shareholder activism. She previously served as Vice President, Corporate Communications at ImClone Systems, where she was a member of the Management Committee and, for 13 years, led the company’s communications department.
Andrea began her career as a compliance analyst at Smith Barney Shearson Inc and holds a J.D. from the Jacob D. Fuchsberg Law Center at Touro College and a B.A. from Boston University.
Select Achievements
- Co-founded, lead, and built Argot Partners resulting in its acquisition by Danforth Health in 2023
- Since the formation of Argot Partners, she has worked with more than 300 biopharmaceutical clients as a senior advisor at key inflection points across the corporate lifecycle
Cynthia Dinella, BS, RPh, Pharm D
Cynthia is the President and Managing Partner of Advyzom, a boutique consulting firm specializing in regulatory strategy, medical writing, and regulatory intelligence for the pharmaceutical and healthcare industries. With over two decades of experience, Cynthia excels at guiding biopharma companies through global and U.S. drug development, working across therapeutic areas to meet health authority requirements.
Cynthia has a Doctor of Pharmacy from St. John’s University and a BS in Pharmacy from Rutgers University.